Zerlasiran (SLN360)
Cardiovascular Risk Reduction (Elevated Lp(a))
Phase 2Active
Key Facts
Indication
Cardiovascular Risk Reduction (Elevated Lp(a))
Phase
Phase 2
Status
Active
Company
About Silence Therapeutics
Silence Therapeutics is a clinical-stage RNA interference (RNAi) company focused on developing novel siRNA therapeutics. As a pioneer in the field, the company's core technology, mRNAi GOLD™, enables the targeted delivery of siRNAs to hepatocytes in the liver. Its lead asset, zerlasiran (SLN360), is in Phase 2 development for cardiovascular risk reduction, and the company has established significant collaborations with AstraZeneca and Hansoh Pharma to expand its pipeline and validate its platform.
View full company profile